A degenerative neurological disorder marked by a progressive loss of motor control is Parkinson's disease (PD).
Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients.
Parkinsons Disease
Parkinson's disease is a neurodegenerative disease caused by progressive dopamine brain cells loss. Symptoms of Parkinson's disease are correctable to an extent.
Advertisement
PD patients were divided into two groups: 20 patients received Exenatide injections for 12 months, while the other group of 24 patients served as controls. Due to high manufacturing costs, the control group did not receive placebo injections and the patients were aware of their group assignment.
Foltynie and colleagues observed that Exenatide was well tolerated. After one year of treatment patients receiving Exenatide displayed improved cognitive ability and motor skills, while control patients declined.
![Drug Firm to Pay Huge Damages to Parkinsons Disease Sufferer]( "Drug Firm to Pay Huge Damages to Parkinsons Disease Sufferer")
A French Parkinson's sufferer who turned into a gambler and thief, with compulsive homosexual urges thanks to the drugs he took, is all set to receive a huge compensation.
Though this trial cannot rule out a placebo effect, the study suggests that Exenatide may improved motor function in PD patients and provides a strong rationale for conducting a larger, blinded study to determine the effectiveness of Exenatide in PD. In the accompanying commentary, Roger Barker (University of Cambridge), Mark Stacy (Duke University) and Patrik Brundin (Van Andel Institute) discuss the novel, cost-saving clinical trial design used in this study.
Source: Eurekalert
Drug Firm to Pay Huge Damages to Parkinsons Disease Sufferer
A French Parkinson's sufferer who turned into a gambler and thief, with compulsive homosexual urges thanks to the drugs he took, is all set to receive a huge compensation.
Advertisement
Though this trial cannot rule out a placebo effect, the study suggests that Exenatide may improved motor function in PD patients and provides a strong rationale for conducting a larger, blinded study to determine the effectiveness of Exenatide in PD. In the accompanying commentary, Roger Barker (University of Cambridge), Mark Stacy (Duke University) and Patrik Brundin (Van Andel Institute) discuss the novel, cost-saving clinical trial design used in this study.
Source: Eurekalert
Nose may Hold Key to Parkinson's Cure
A new study from Griffith University suggests that Parkinson's patients' nose may harbour a cure for the disease.
Advertisement
 Robot Controlled by Cables may Help in Stroke and Parkinson’s PatientsA unique robotic device has been developed by experts at Florida Atlantic University. This robot may prove useful in rehabilitating patients suffering from Parkinson's disease and stroke. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Diagnosed autistic individuals showed increased premature mortality in the UK, highlighting urgent needs to address associated inequalities.
Study reveals a correlation between hearing impairment and distinct brain region variances, contributing to dementia.
Financial impact of caring for individuals with neurodegenerative disorders reaches hundreds of billions annually in the United States.
Experts emphasize that addressing the skills gap demands immediate attention and innovative solutions, including education, re-training, and significant time investment.
New study unveiled the cells' ability to adapt in responses and potential implications for conditions such as diabetes and cancer.